Ventyx Biosciences (VTYX)
(Delayed Data from NSDQ)
$1.97 USD
-0.05 (-2.48%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $1.98 +0.01 (0.51%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VTYX 1.97 -0.05(-2.48%)
Will VTYX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for VTYX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTYX
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
VTYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VTYX
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
Ventyx Biosciences: Strong Financial Position and Promising Pipeline Drive Buy Rating
Ventyx Biosciences (VTYX) Gets a Buy from Oppenheimer
Ventyx Biosciences (VTYX) Receives a Buy from LifeSci Capital
Hold Rating for Ventyx Biosciences Amid Promising Developments and Strategic Uncertainties